With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Kalkine Media, GuruFocus, Investor's Business Daily and STAT. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 1h ago.
Quick answers
Why is "With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company ch" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (6)
- TD Cowen reiterates Alkermes stock Buy rating on ADHD trial data By Investing.com Investing.com South Africa · 9h ago
- Alkermes Announces Positive Phase 1 Topline Results for ALKS 7290 in ADHD Treatment Kalkine Media · 9h ago
- ALKS Reiterates by Needham -- Price Target Maintained at $62.00 GuruFocus · 9h ago
- What This Biotech Learned From Narcolepsy And Took To ADHD Investor's Business Daily · 9h ago
- Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial STAT · 9h ago
- With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’ Fierce Biotech · 9h ago
Topics
Related trends
Porsche Is Planning A New Supercar With A Flat-Eight Engine: Report
5 news sources are covering this Technology story right now — PULSE is tracking how fast it spreads.
2027 Nissan Rogue Hybrid Debuts With 38 MPG. But It's Not A Traditional Hybrid
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Paramount Settles Antitrust Case With State A.G.s, Removing Obstacle to Warner Bros. Deal
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
What's Going On With Rocket Lab Stock Monday?
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Putin Reignited a Dispute With Japan. This Town Is Stuck in the Middle.
5 news sources are covering this World story right now — PULSE is tracking how fast it spreads.
Kuehne+Nagel Strikes Deal With Amazon For Supply Chain, Cloud Capabilities
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.